Enlivex Jumps 67% Amid Launch of RAIN Protocol Digital Treasury

Introduction

Enlivex Therapeutics Ltd (Nasdaq: ENLV) is a clinical-stage biopharmaceutical company headquartered in Nes Ziona, Israel. The company develops Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages for the treatment of inflammatory diseases. On November 24, 2025, ENLV closed at $1.50, reflecting a 67.26% increase, with a trading volume of approximately 15.96 million shares.

Corporate Structure and Experience

Enlivex employs between 11 and 50 people, including experts in immunotherapy, cell biology, clinical operations, and regulatory affairs. Co-founder Professor Dror Mevorach is known for his work in developing the apoptotic cell-based platform underlying Allocetra™. In 2015, three executives with previous experience in commercializing PROLOR Biotech’s ngenla joined Enlivex to support the therapy’s development. The board includes members with diverse backgrounds, including former Italian Prime Minister Matteo Renzi.

Cell therapy by Harper Sunday

Developments and News

• November 18, 2025: Filing of Form 6-K reporting the outcomes of the 2025 Annual General Meeting, during which all shareholder proposals were approved.
• November 14, 2025: Submission of unaudited condensed consolidated financial statements and Operating and Financial Review for the three and nine months ended September 30, 2025 (Form 6-K, Exhibit 99.1 and 99.2).
• November 10, 2025: Adjournment of the Annual General Meeting due to lack of quorum; meeting reconvened on November 17, 2025.
• November 24, 2025: Announcement that upon closing a private placement, Enlivex will adopt a digital asset treasury strategy based on the RAIN protocol, aimed at enhancing capital efficiency through token accumulation.
• October 28, 2025: Presentation of a late-breaking poster abstract at the American College of Rheumatology Convergence 2025 on Allocetra™ data.
• September 29, 2025: An investor webinar hosted by D. Boral Capital titled “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex’s Knee Osteoarthritis Program.”
• September 11, 2025: Publication of efficacy data from the Phase IIa randomized, multi-country trial (ENX-CL-05-001) in moderate to severe knee osteoarthritis, with Phase IIb initiation planned for Q2 2026.

Financial and Strategic Analysis

As of November 24, 2025, Enlivex’s market capitalization was approximately $21.8 million, with 24.29 million shares outstanding. The 52-week trading range is $0.83–$2.10. The trailing twelve-month EPS stands at –0.55, resulting in a P/E ratio of –1.64; the forward P/E is –1.72. The company maintains a beta of 1.51.

Enlivex is strategically positioned to balance clinical development with innovative capital management. The RAIN protocol treasury initiative represents a move towards diversifying funding sources. Allocetra™ is progressing through Phase II trials across several indications, including sepsis-related organ failure, knee and thumb osteoarthritis, and psoriatic arthritis, supported by a favorable safety profile in over 150 treated patients.

Market Position and Industry Context

Enlivex operates within the cell therapy segment of the broader immunotherapy market, addressing acute and chronic inflammatory diseases with significant unmet needs. By focusing on macrophage reprogramming, the company seeks to differentiate its approach from conventional therapies such as cytokine inhibitors and small-molecule anti-inflammatories. The global osteoarthritis and sepsis markets are valued in the multi-billion-dollar range. Enlivex’s off-the-shelf, frozen product format aims to streamline manufacturing processes and reduce costs compared to autologous cell therapies, positioning it competitively among emerging immunomodulatory platforms.

tl;dr

On November 24, 2025, ENLV shares increased by 67.26% to $1.50. In the preceding weeks, Enlivex conducted and reconvened its Annual General Meeting (Form 6-K filings on November 10 and 18), filed Q3 2025 financials on November 14, and announced a RAIN protocol digital asset treasury strategy on November 24. The company also presented Phase IIa knee osteoarthritis data on September 11, 2025, with plans for Phase IIb in Q2 2026. Upcoming milestones include ongoing Phase II trials in osteoarthritis and sepsis and continued implementation of its token-based treasury strategy.